Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer

Olshan, Andrew F.

doi:10.1007/978-1-4419-1472-9

Cited by 12 publications

(7 citation statements)

References 463 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results support the epidemiological evidence that some head and neck cancers are caused by HPV and that the main risk factors of HNSCC are tobacco and alcohol abuse [1]. The overall prevalence of HPV in the HNSCC group was 42.1%, which is in line with a large number of reports of HPV DNA (2.4-74%) in head and neck cancer patients [8,[31][32][33]40,[50][51][52][53][54][55][56][57][58][59]. The data concerning HPV infection in HNSCC patients in Poland are very inconclusive.…”

Section: Hpv Infection In Hnsccsupporting

confidence: 89%

“…HPV detection and identification of subtypes were performed by GenoFlow HPV (Human Papillomavirus) Array Test Kits (DiagCor Bioscience Inc., Hong Kong) which use biotin-labeled primers, specific probes, PCR and "flow-through" hybridization technology, which allows detection of 33 common HPV subtypes. The following are considered highrisk (16,18,31,33,35,39,45,51,52,53,56,58,59,66,68,73,82) and low-risk (6,11,26,40,42,43,44,54,55,57,61,70,71,72,81,84) subtypes based on their phylogenetic and epidemiological criteria and the biological niche. The extracted DNA was mixed with PCR reagent mix and DNA Taq Polymerase provided with the kit and amplified using a Mastercycler Personal Thermal Cycler (Eppendorf, Hamburg, Germany) according to the manufacturer's protocol.…”

Section: Hpv Detection and Type Determinationmentioning

confidence: 99%

See 1 more Smart Citation

The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland

et al. 2021

View full text Add to dashboard Cite

Human papillomavirus (HPV) is a virus with the potential to infect human epithelial cells and an etiological agent of many types of cancer, including head and neck cancer. The aim of the study was to determine the prevalence of HPV infection in patients with head and neck squamous cell carcinoma (HNSCC), patients with chronic tonsillitis, and healthy individuals, and to establish high- and low-risk HPV genotypes in these groups. The objectives also comprised the delineation of the relationship between the infection with high- or low-risk HPV subtypes and clinicopathological and demographic characteristics of the study groups. This study was composed of 76 patients diagnosed with HNSCC, 71 patients with chronic tonsillitis, and 168 cases without either of these conditions (the control group). HPV detection and identification of subtypes were performed on isolated DNA using a test which allowed detection of 33 common high-risk and low-risk HPV subtypes. The prevalence of HPV infection was 42.1%, 25.4%, and 37.5% in HNSCC, chronic tonsillitis, and control groups, respectively. HPV 16 was the most prevalent genotype in all groups and the non-oncogenic HPV 43/44 was frequent in HNSCC patients. This analysis provides insight into the prevalence of oral oncogenic and non-oncogenic HPVs in patients with head and neck cancer, patients with chronic tonsillitis and healthy individuals, and leads to the conclusion that further investigations are warranted to examine a larger cohort of patients focusing on high- and low-risk HPV genotypes. Efforts should be focused on screening and prevention strategies, and therefore, it is important to introduce tools for effective detection of HPV genotypes. Furthermore, given the role of vaccines against oral HPV infection, our observations lead to the suggestion that HPV vaccination should be of considerable importance in public health strategies.

show abstract

Section: Hpv Infection In Hnsccsupporting

confidence: 89%

Section: Hpv Detection and Type Determinationmentioning

confidence: 99%

The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Patients with NPC are mostly males with a known history of tobacco and heavy alcohol use [19], and our data reflects what has been previously reported as 65% were males with 71% had a known history of tobacco and 51% had a history of heavy alcohol use. Nasopharyngeal carcinoma is more common in Asians/Pacific Islanders, who are diagnosed six times more frequently than Caucasian and Hispanic people [20], and in whom the disease can occur at any age, including children, while about 50% of people with the disease are 55 years or younger. Our patient cohort consisted of 39% Caucasian and 55 % African Americans, which is most likely due to our regional demographics, while 53% of the cohort were younger than 60 years.…”

Section: Discussionmentioning

confidence: 99%

Quality-Adjusted Life Years and Disability-Adjusted Life Years Are Better With Concurrent Chemoradiation Therapy Than Induction Chemotherapy Followed by Chemoradiation Therapy in Nasopharyngeal Carcinoma

Nittala¹,

Kanakamedala²,

Mundra³

et al. 2021

Cureus

View full text Add to dashboard Cite

Introduction As traditional measures such as overall survival (OS) or disease-free survival (DFS) alone do not give a holistic view of the outcomes of a treatment paradigm, we determine to add the evidence of quality-adjusted life year (QALY) and disability-adjusted life year (DALY) to the outcomes of the nasopharyngeal carcinoma patients (NCP) treated with definitive chemoradiation therapy (chemoRT) with or without induction chemotherapy (induction chemo). Methods This is a retrospective analysis of 85 NCPs treated at an academic state institution. The OS estimated by the Kaplan-Meier method and the multivariate Cox regression model determined the co-variables associated with the OS. The relationship between QALYs gained and DALYs saved were calculated from age of the disease onset, duration of the disease, quality of life (QoL) and disability weights. Results Of the 85 eligible NCPs of this cohort, the disease frequency distribution per the World Health Organization (WHO) classification was 41.2% for Type-I, 42.4% for Type-II, and 16.5% for Type-III. The median follow-up (24 months). The five-year OS of patients treated with concurrent chemoRT vs . induction chemo followed by concurrent chemoRT was 54.7 vs . 14.8% for WHO Type I, 60.1 vs. 58.3% for WHO Type II, and 83.3 vs. 50.0% for WHO Type III (p=0.029). The average DALYs saved with concurrent chemoRT were 12.2 years vs. 5 years for induction chemo followed by concurrent chemoRT. The average QALYs gained with concurrent chemoRT were 6.9 years vs. 3.1 years for induction chemo followed by concurrent chemoRT. Conclusion Patients treated with concurrent chemoRT had an increased QoL when compared to induction chemo followed by concurrent chemoRT. The average DALYs saved were higher in the patients treated with concurrent chemoRT than treated with induction chemo followed by concurrent chemoRT.

show abstract

“…HPV can infect the basal cell layer of human epithelium, inducing benign hyperproliferations or promoting premalignant lesions. 3 HPV16, the HR variant, accounts for a large number of HNSCC cases. 29 All papillomaviruses share a common genomic structure characterized by eight open reading frames, including early genes (E1, E2, E4, E5, E6, and E7), late genes (L1 and L2), and the long control region (LCR) or upstream regulatory region (URR).…”

Section: The Hpv16 Genome and Viral Oncogenesmentioning

confidence: 99%

“…HNCs are a group of malignancies affecting the upper region of the respiratory and digestive tracts, 1 with the most common type being head and neck squamous cell carcinoma (HNSCC). 2,3 HNC has gained clinical attention due to its relationship with the high-risk HPV (HR HPV), with HPV16 and 18 collectively accounting for 85% of HNC cases worldwide. 4 It is now understood that HPV16 is the predominant causal type that presents in 69.2% of laryngeal cancers and 68.2% of oral cavity cancers.…”

Section: Epidemiologymentioning

confidence: 99%

Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management

Tran,

Sais,

Tran

2024

Journal of Medical Virology

View full text Add to dashboard Cite

Head and neck cancers (HNCs), primarily head and neck squamous cell carcinoma (HNSCC), are associated with high‐risk human papillomavirus (HR HPV), notably HPV16 and HPV18. HPV status guides treatment and predicts outcomes, with distinct molecular pathways in HPV‐driven HNSCC influencing survival rates. HNC incidence is rising globally, with regional variations reflecting diverse risk factors, including tobacco, alcohol, and HPV infection. Oropharyngeal cancers attributed to HPV have significantly increased, particularly in regions like the United States. The HPV16 genome, characterized by oncoproteins E6 and E7, disrupts crucial cell cycle regulators, including tumor protein p53 (TP53) and retinoblastoma (Rb), contributing to HNSCC pathogenesis. P16 immunohistochemistry (IHC) is a reliable surrogate marker for HPV16 positivity, while in situ hybridization and polymerase chain reaction (PCR) techniques, notably reverse transcription‐quantitative PCR (RT‐qPCR), offer sensitive HPV detection. Liquid‐based RT‐qPCR, especially in saliva, shows promise for noninvasive HPV detection, offering simplicity, cost‐effectiveness, and patient compliance. These molecular advancements enhance diagnostic accuracy, guide treatment decisions, and improve patient outcomes in HNC management. In conclusion, advances in HPV detection and molecular understanding have significant clinical management implications. Integrating these advancements into routine practice could ultimately improve patient outcomes.

show abstract

Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer

Cited by 12 publications

References 463 publications

The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland

The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland

Quality-Adjusted Life Years and Disability-Adjusted Life Years Are Better With Concurrent Chemoradiation Therapy Than Induction Chemotherapy Followed by Chemoradiation Therapy in Nasopharyngeal Carcinoma

Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management

Contact Info

Product

Resources

About